A Look At CONMED (CNMD) Valuation After Earnings And Growth In Key Surgical Segments
CONMED (CNMD) shares were in focus after the company reported fourth quarter and full year 2025 results, issued 2026 revenue guidance, and highlighted momentum in orthopedics and high growth surgical segments.
See our latest analysis for CONMED.
At a share price of US$39.93, CONMED has seen short term momentum pick up, with a 1 day share price return of 2.94% and 7 day share price return of 3.21%. However, the 1 year total shareholder return of 45.45% and 5 year total shareholder return of 64.97% show longer term pressure. This frames recent enthusiasm around earnings, guidance and the focus on higher growth surgical segments as a potential shift in how markets are weighing its risks and prospects.
If this kind of earnings driven move has your attention, it could be a good moment to scan other medical names using our screener for healthcare stocks.
With the shares down over the past year despite revenue growth, and trading at a sizeable discount to one valuation estimate, investors now have to ask whether CONMED represents mispriced value or if the market already anticipates future growth.
Most Popular Narrative: 17.5% Undervalued
At $39.93, the most followed narrative pegs CONMED’s fair value at $48.40, which suggests a sizeable gap that hinges on a long term earnings story built on a 9.17% discount rate.
The accelerating adoption of minimally invasive and robotic-assisted surgeries, combined with CONMED's strong positioning via AirSeal and BioBrace (including expanding use cases and positive clinical feedback), is poised to support durable procedure volume growth and increase recurring revenue, driving sustained top-line growth.
Curious what has to happen for that projected earnings curve to line up with a higher fair value, while still using a lower P/E than many medical device peers and a disciplined discount rate that keeps the bar from drifting too high.
Result: Fair Value of $48.40 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still need to weigh up ongoing supply chain issues in orthopedics and pressure on hospital capital budgets, either of which could challenge the long term earnings story.
Find out about the key risks to this CONMED narrative.
Build Your Own CONMED Narrative
If the current fair value story does not quite fit your view, you can stress test the same data, tweak the assumptions, and Do it your way in just a few minutes.
A great starting point for your CONMED research is our analysis highlighting 4 key rewards and 4 important warning signs that could impact your investment decision.
Looking for more investment ideas?
If CONMED has sparked your interest, do not stop there. The Simply Wall St Screener can quickly surface other opportunities that might suit your style and goals.
- Scan for value by using these 866 undervalued stocks based on cash flows which flags companies trading below their estimated cash flow based worth.
- Capitalize on sector shifts with these 19 cryptocurrency and blockchain stocks which targets businesses tied to cryptocurrency and blockchain themes.
- Level up your income focus through these 11 dividend stocks with yields > 3% highlighting companies with dividend yields above 3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com